Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital cuts target price on Warpaint

(Sharecast News) - RBC Capital Markets has more than halved its target price for Warpaint London, after the AIM-listed cosmetics firm cut its full-year guidance. The broker said it had reset its 2025 forecasts following Warpaint's disappointing interim results, published last month. It now expects adjusted EBITDA of £24.4m on revenues of £107.8m.

It also cut its target price for the company, which owns W7, Technic and Dirty Works, among other brands, to 440p from 700p.

But it retained its 'outperform' rating.

RBC said: "The unexpected loss of a key Technic customer to administration, changing customer buyer patterns, weakening sentiment and dollar volatility are driving a more conservative outlook than we previously expected."

It concluded: "We believe W7L's medium-term strategy remains intact, despite these near-term challenges.

"Our revised 440p price target reflects a multiple of 12.5x 2026 EV/adjusted EBITDA.

"While investors may pause to re-assess growth prospects in these more uncertain markets, we believe the current trading at 6x EV/adjusted EBITDA is overdone and maintain an 'outperform' rating."

As at 1400 BST, shares in Warpaint were off 2% at 216p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.